I-Mab ADR (IMAB) News
Filter IMAB News Items
IMAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMAB News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IMAB News From Around the Web
Below are the latest news stories about I-MAB that investors may wish to consider to help them evaluate IMAB as an investment opportunity.
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board MemberI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the Company has been informed that Wei Fu, the Chairman of the Board, intends to purchase up to $2,000,000 of the Company's ADSs in open market transactions. As the planned purchases are to be executed by Wei Fu via his controlled entity, I-Mab cannot guarantee the number of ADSs to be purchased or the time frame i |
US Penny Stocks To Watch In January 2025As the U.S. stock market navigates rising Treasury yields and strong economic data, investors are keenly watching how these factors might influence interest rates and broader market movements. Penny stocks, a term that may seem outdated but remains relevant, often represent smaller or less-established companies with potential value. By focusing on those with robust financials and clear growth prospects, investors can uncover opportunities in these under-the-radar stocks that might offer both... |
I-Mab pauses CD73 antibody development in pipeline reshuffleI-Mab has paused the development of uliledlimab to focus on a Phase I trial of its lead candidate givastomig. |
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical ProgramI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today highlighted its strategic outlook for 2025 and a re-prioritization of resources, with a focus on advancing its lead program, givastomig, a CLDN18.2 x 4-1BB bispecific antibody, targeting first-line metastatic gastric cancers, with further potential in other solid tumors. |
I-Mab Leads Our Spotlight On 3 US Penny StocksAs the S&P 500 and Nasdaq hit record highs, the U.S. stock market continues its post-election rally with optimism among investors. Amidst this backdrop, penny stocks remain a fascinating segment of the market, often representing smaller or newer companies that can offer unique opportunities for growth. While the term 'penny stocks' might seem outdated, they still hold relevance for those looking to explore investments beyond established giants; here we spotlight three such stocks that stand... |
I-Mab to Participate at the Piper Sandler Healthcare ConferenceI-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. |
I-Mab Third Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)I-Mab ( NASDAQ:IMAB ) Third Quarter 2024 Results Key Financial Results Net loss: US$20.5m (loss narrowed by 57% from 3Q... |
I-Mab Reports Third Quarter 2024 ResultsI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended September 30, 2024, and highlighted recent pipeline progress and business updates. |
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive OfficerI-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company's permanent Chief Executive Officer ("CEO") effective November 1, 2024. Dr. Fu has served as Interim CEO since July 15, 2024. Dr. Fu will continue to serve as a member of the Board of Directors of I-Mab. |
I-Mab to Release Q3 2024 Financial Results on November 14, 2024I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. |